AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

This was the stock's second consecutive day of gains.

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

The global biopharma firm will build a new API production facility near its global headquarters in North Chicago.

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...